Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRL1 | P41146 | 10/20 | 0.50 |
| ▸ | OPRM1 | P35372 | 9/20 | 0.50 |
| ▸ | OPRD1 | P41143 | 9/20 | 0.50 |
| ▸ | OPRK1 | P41145 | 9/20 | 0.50 |
| ▸ | IDO1 | P14902 | 1/20 | 0.44 |
| ▸ | DRD2 | P14416 | 2/20 | 0.43 |
| ▸ | DRD4 | P21917 | 2/20 | 0.43 |
| ▸ | DRD3 | P35462 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | CCR1 | P32246 | 1/20 | 0.41 |
| ▸ | MLKL | Q8NB16 | 1/20 | 0.40 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4148419 | 0.89 | OPRM1 (0.50) | OPRL1OPRM1OPRD1OPRK1IDO1 | |
| SCHEMBL28722124 | 0.76 | MAPT (0.52) | IDO1MAPTMLKLTAAR1ALDH1A1 | |
| SCHEMBL4933877 | 0.75 | BCHE (0.53) | IDO1MAPTMLKLTAAR1ALDH1A1 | |
| SCHEMBL4155864 | 0.74 | MAPT (0.46) | OPRL1OPRM1OPRD1IDO1MAPT | |
| SCHEMBL4929684 | 0.74 | MAPT (0.50) | IDO1MAPTMLKLTAAR1ALDH1A1 | |
| SCHEMBL23901648 | 0.72 | OPRL1 (0.63) | OPRL1OPRM1OPRD1OPRK1CCR1 | |
| SCHEMBL5329879 | 0.68 | IDO1 (0.46) | IDO1MAPTMLKLTAAR1ALDH1A1 | |
| SCHEMBL17494004 | 0.67 | PIM1 (0.42) | OPRM1MAPTALDH1A1 | |
| SCHEMBL5321876 | 0.66 | TAAR1 (0.48) | IDO1MAPTMLKLTAAR1ALDH1A1 | |
| SCHEMBL19491063 | 0.65 | OPRL1 (0.53) | OPRL1OPRM1OPRD1OPRK1DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090192169-A1 | Bicyclic Benzimidazole Compounds and Their Use as Metabotropic Glutamate Receptor Potentiators | ASTRAZENECA AB (SE) | 2009-07-30 | — | — | US | claimed |
| EP-2004613-A2 | BICYCLIC BENZIMIDAZOLE COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR POTENTIATORS | AstraZeneca AB (SE) | 2008-12-24 | — | — | EP | claimed |
| WO-2007115077-A2 | BICYCLIC BENZIMIDAZOLE COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR POTENTIATORS | ASTRAZENECA AB (SE) | 2007-10-11 | — | — | WO | claimed |
| US-20090192169-A1 | Bicyclic Benzimidazole Compounds and Their Use as Metabotropic Glutamate Receptor Potentiators | ASTRAZENECA AB (SE) | 2009-07-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090192169-A1 | Bicyclic Benzimidazole Compounds and Their Use as Metabotropic Glutamate Receptor Potentiators | GRM1, GRIN1, GRM2 | OPRL1 96/4885OPRM1 141/4885OPRD1 106/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.